EZH2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes <i>CASZ1</i> , <i>CLU</i> , <i>RUNX3</i> , and <i>NGFR</i>

Chunxi Wang(National Institute of Diabetes and Digestive and Kidney Diseases), Carol J. Thiele(National Cancer Institute), Javed Khan(Kent State University), Kai Ge(West Anhui University), Jun S. Wei(Center for Cancer Research), Chan-Wook Woo(National Institute of Diabetes and Digestive and Kidney Diseases), Zhihui Liu(Jilin University), Zhijie Li(University of Iowa), Lifeng Wang(China National Hybrid Rice R&D Central Hunan Hybrid Rice Reserch Center), Qihuang Jin(Shanghai Jiao Tong University), Víctor E. Márquez(Hospital la Serena), Susan E. Bates(The Nature Conservancy)
Cancer Research
November 9, 2011
10.1158/0008-5472.can-11-0961
Cited by 179

Related Papers

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks
|Nature Medicine|2001|2.7k
The genetic landscape of high-risk neuroblastoma
|Nature Genetics|2013|1.2k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Distinct roles of GCN5/PCAF‐mediated H3K9ac and CBP/p300‐mediated H3K18/27ac in nuclear receptor transactivation
|The EMBO Journal|2010|904
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
|Cancer Discovery|2014|789